Topographical distribution of allelic loss in individual lung adenocarcinomas with lymph node metastases

Modern Pathology

Volumn 17, Issue 2, 2004, Pages 204-213

  Yoshikawal, Takeshi ^a,b,c   Aoyagi, Yasuyuki ^a   Kodama, Keiji ^a   Kamijo, Tomoyuki ^a   Yonou, Hiroyuki ^a   Yokose, Tomoyuki ^a   Ishii, Genichiro ^a   Oda, Tatsuya ^a   Takamochi, Kazuya ^b   Nagai, Kanji ^b   Nishiwaki, Yutaka ^b   Shimizu, Nobuyoshi ^c   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Loss of heterozygosity; Lung adenocarcinoma; Lymph node metastasis; Microdissection; Topography

Indexed keywords

ALLELE; ARTICLE; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 5P; CONTROLLED STUDY; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LYMPH NODE METASTASIS; MORPHOLOGY; PRIORITY JOURNAL; TOPOGRAPHY; ADENOCARCINOMA; GENETICS; LUNG TUMOR; PATHOLOGY;

DNA;

ADENOCARCINOMA; DNA, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; LYMPHATIC METASTASIS;

EID: 4644247249     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800035     Document Type: Article

References (39)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
2. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumours, 3rd edn. Springer-Verlag: Heidelberg, 1999.
3. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
4. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70:1727-1731.
5. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-7722.
6. Aoyagi Y, Yokose T, Minami Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001;61:7950-7954.
7. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-2852.
8. Shiseki M, Kohno T, Adachi J, et al. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 1996;17:71-77.
9. Wistuba, II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:643-650.
10. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:998-1003.
11. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 2000;19, I-XI 193-383.
12. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60:7052-7056.
13. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 1996;84:587-597.
14. Sanchez-Cespedes M, Rosell R, Pifarre A, et al. Microsatellite alterations at 5q21, 11p13, and 11p155 do not predict survival in non-small cell lung cancer. Clin Cancer Res 1997;3:1229-1235.
15. Tsutsumi M, Tsai YC, Gonzalgo ML, et al. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogene 1998;17:3021-3027.
16. Okami K, Cairns P, Westra WH, et al. Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer 1997;74:588-592.
17. Ogawara K, Miyakawa A, Shiba M, et al. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int J Cancer 1998;79:312-317.
18. Goto A, Kanda H, Ishikawa Y, et al. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 1998;89:539-547.
19. Takei K, Kohno T, Hamada K, et al. A novel tumor suppressor locus on chromosome 18q involved in the development of human lung cancer. Cancer Res 1998;58:3700-3705.
20. Anami Y, Takeuchi T, Mase K, et al. Amplotyping of microdissected, methanol-fixed lung carcinoma by arbitrarily primed polymerase chain reaction. Int J Cancer 2000;89:19-25.
21. Langenbach N, Kroiss MM, Ruschoff J, Schlegel J, et al. Assessment of microsatellite instability and loss of heterozygosity in sporadic keratoacanthomas. Arch Dermatol Res 1999;291:1-5.
22. Takamochi K, Ogura T, Suzuki K, et al. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 2001;159:1941-1948.
23. Boland CR, Sato J, Appelman HD, et al. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med 1995;1:902-909.
24. Yatabe Y, Konishi H, Mitsudomi T, et al. Topographical distributions of allelic loss in individual non-small-cell lung cancers. Am J Pathol 2000;157:985-993.
25. Sasatomi E, Finkelstein SD, Woods JD, et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 2002;62:2681-2689.
26. Havre PA, Yuan J, Hedrick L, et al. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995;55:4420-4424.
27. Fukasawa K, Choi T, Kuriyama R, et al. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-1747.
28. Bertrand P, Rouillard D, Boulet A, et al. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene 1997;14:1117-1122.
29. Kohno T, Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 1999;20:1403-1410.
30. Thiberville L, Bourguignon J, Metayer J, et al. Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. Int J Cancer 1995;64:371-377.
31. Sanz-Ortega J, Bryant B, Sanz-Esponera J, et al. LOH at the APC/MCC gene (5Q21) is frequent in early stages of non-small cell lung cancer. Pathol Res Pract 1999;195:677-680.
32. Tomizawa Y, Adachi J, Kohno T, et al. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 1999;5:1139-1146.
33. Fong KM, Kida Y, Zimmerman PV, et al. MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer. Br J Cancer 1996;74:1975-1978.
34. Chizhikov V, Zborovskaya I, Laktionov K, et al. Two consistently deleted regions within chromosome 1p32-pter in human non-small cell lung cancer. Mol Carcinog 2001;30:151-158.
35. Mitsudomi T, Oyama T, Nishida K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 1996;2:1185-1189.
36. Osaki T, Oyama T, Inoue M, et al. Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg 2001;49:545-551.
37. Burke L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998;58:2533-2536.
38. Fong KM, Zimmerman PV, Smith PJ. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 1995;55:220-223.
39. Fong KM, Kida Y, Zimmerman PV, et al. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 1995;55:4268-4272.